blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3845531

EP3845531 - SUBSTITUTED PYRAZOLE FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  06.06.2024
Database last updated on 16.07.2024
FormerRequest for examination was made
Status updated on  04.06.2021
FormerThe international publication has been made
Status updated on  05.04.2020
Most recent event   Tooltip07.06.2024First examination report 
Applicant(s)For all designated states
Applied Pharmaceutical Science, Inc.
C10-1, BDA, 2 North Jingyuan Street
Beijing 100176 / CN
[2021/27]
Inventor(s)01 / WANG, Zhijian
2 North, JingyuanSt., C10-1, BDA
Beijing 100176 / CN
02 / ZHONG, Jun
2 North, JingyuanSt., C10-1, BDA
Beijing 100176 / CN
03 / WANG, Xuebing
2 North, JingyuanSt., C10-1, BDA
Beijing 100176 / CN
 [2021/27]
Representative(s)Gille Hrabal Partnerschaftsgesellschaft mbB Patentanwälte
Brucknerstraße 20
40593 Düsseldorf / DE
[2021/27]
Application number, filing date19865058.230.09.2019
[2021/27]
WO2019CN109502
Priority number, dateCN20181116249730.09.2018         Original published format: CN201811162497
[2021/27]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020064009
Date:02.04.2020
Language:ZH
[2020/14]
Type: A1 Application with search report 
No.:EP3845531
Date:07.07.2021
Language:EN
[2021/27]
Search report(s)International search report - published on:CN02.04.2020
(Supplementary) European search report - dispatched on:EP27.10.2021
ClassificationIPC:C07D471/04, C07D487/04, A61K31/4985, A61K31/4162, A61P35/00, A61P1/00, C07D519/00
[2021/47]
CPC:
A61K45/06 (EP); C07D471/04 (EP,CN,KR,US); A61K31/496 (KR,US);
A61K31/4162 (KR); A61K31/4427 (KR); A61K31/444 (KR);
A61K31/4545 (KR,US); A61K31/4995 (US); A61P1/00 (EP,CN,KR);
A61P1/12 (EP,CN,KR); A61P29/00 (EP,CN,KR); A61P35/00 (EP,CN,KR,US);
C07D487/04 (KR); C07D519/00 (EP,CN,US) (-)
Former IPC [2021/27]C07D471/04, C07D487/04, A61K31/4985, A61K31/4162, A61P35/00, A61P1/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/27]
TitleGerman:SUBSTITUIERTE PYRAZOLKONDENSIERTE RINGDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND ANWENDUNG DAVON[2021/27]
English:SUBSTITUTED PYRAZOLE FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF[2021/27]
French:DÉRIVÉ CYCLIQUE CONDENSÉ À UN PYRAZOLE SUBSTITUÉ, SON PROCÉDÉ DE PRÉPARATION ET APPLICATION ASSOCIÉE[2021/27]
Entry into regional phase31.03.2021Translation filed 
31.03.2021National basic fee paid 
31.03.2021Search fee paid 
31.03.2021Designation fee(s) paid 
31.03.2021Examination fee paid 
Examination procedure31.03.2021Examination requested  [2021/27]
23.05.2022Amendment by applicant (claims and/or description)
05.06.2024Despatch of a communication from the examining division (Time limit: M04)
Fees paidRenewal fee
30.08.2021Renewal fee patent year 03
26.08.2022Renewal fee patent year 04
22.08.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]WO2017011776  (ARRAY BIOPHARMA INC [US]);
 [XI]WO2018071454  (ANDREWS STEVEN W [US], et al);
 [XI]WO2018071447  (ANDREWS STEVEN W [US], et al);
 [XI]WO2018136661  (ANDREWS STEVEN W [US], et al)
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.